U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H19N3O3S
Molecular Weight 345.4178
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OMEPRAZOLE

SMILES

Cc1cnc(CS(=O)c2nc3ccc(cc3[nH]2)OC)c(C)c1OC

InChI

InChIKey=SUBDBMMJDZJVOS-UHFFFAOYSA-N
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)

HIDE SMILES / InChI

Molecular Formula C17H19N3O3S
Molecular Weight 345.4178
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Esomeprazole strontium is a proton pump inhibitor. It suppresses gastric acid secretion by specific inhibition H+/K+ ATPase in the gastric parietal cell. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity. The drug is indicated for the treatment of gastroesophageal reflux disease, reduction the risk of NSAID-associated gastric ulcer, eradication of H.pylori, and pathological hypersecretory conditions.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in mouse. Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NEXIUM 24HR

Approved Use

treats frequent heartburn (occurs 2 or more days a week)

Launch Date

1.3958784E12
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

1.20597119E12
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

1.20597119E12
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

6.217344E11
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

1.20597119E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.5 μM
40 mg 1 times / day multiple, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ESOMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
668 ng/mL
1 mg/kg single, oral
dose: 1 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
16.2 μM × h
40 mg 1 times / day multiple, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ESOMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1220 ng × h/mL
1 mg/kg single, oral
dose: 1 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1179 nM × h
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1200 nM*h
20 mg single, oral
dose: 20 mg
route of administration: oral
experiment type: single
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: healthy
age: adults
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.4 h
40 mg 1 times / day multiple, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ESOMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.58 h
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
n = 161
Health Status: unhealthy
Condition: reflux oesophagitis
Age Group: 45.2
Sex: M+F
Population Size: 161
Sources:
Other AEs: Nausea, Diarrhoea...
Other AEs:
Nausea (7%)
Diarrhoea (6%)
Headache (3%)
Sources:
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Other AEs: Headache, Abdominal pain...
Other AEs:
Headache (6.9%)
Abdominal pain (5.2%)
Nausea (4%)
Diarrhea (3.7%)
Vomiting (3.2%)
Flatulence (2.7%)
Esophageal acid reflux (1.9%)
Upper respiratory infection (1.9%)
Constipation (1.5%)
Dizziness (1.5%)
Rash (1.5%)
Asthenia (1.3%)
Back pain (1.1%)
Cough (1.1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
n = 161
Health Status: unhealthy
Condition: reflux oesophagitis
Age Group: 45.2
Sex: M+F
Population Size: 161
Sources:
Diarrhoea 6%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
n = 161
Health Status: unhealthy
Condition: reflux oesophagitis
Age Group: 45.2
Sex: M+F
Population Size: 161
Sources:
Nausea 7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
n = 161
Health Status: unhealthy
Condition: reflux oesophagitis
Age Group: 45.2
Sex: M+F
Population Size: 161
Sources:
Back pain 1.1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Cough 1.1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Asthenia 1.3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Constipation 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Dizziness 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Rash 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Esophageal acid reflux 1.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Upper respiratory infection 1.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Flatulence 2.7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Vomiting 3.2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Diarrhea 3.7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Nausea 4%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Abdominal pain 5.2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
Headache 6.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 3096
Health Status: unhealthy
Condition: Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome
Population Size: 3096
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
strong [IC50 3.7 uM]
yes (co-administration study)
Comment: Esomeprazole administration resulted in a significant increase (1.67‐fold) in the AUC0–∞ of proguanil and a significant decrease (0.522‐fold) in that of cycloguanil
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [Ki 150 uM]
weak (co-administration study)
Comment: Omeprazole exerts a concentration-dependent inhibition of CYP1A2 activity in man. However, even after single oral doses up to 80 mg, this effect is weak and without clinical relevance
weak [Ki 367.5 uM]
weak [Ki 745.1 uM]
yes [IC50 1.2 uM]
likely (co-administration study)
Comment: The frequency of delayed MTX elimination in patients administered esomeprazole was 71.4%
yes [IC50 15.7 uM]
yes [IC50 17.6 uM]
yes [IC50 17.7 uM]
yes [IC50 22 uM]
yes [IC50 4.32 uM]
yes [IC50 6.7 uM]
yes [IC50 6.8 uM]
yes [IC50 84.3 uM]
unlikely (co-administration study)
Comment: Coaministration with simvastatin acid unlikely results in DDIs
yes [Ki 7.1 uM]
yes (co-administration study)
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes (expression study)
Comment: livers of patients treated with omeprazole showed higher MRP3 protein expression
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: When voriconazole was given with omeprazole to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times and 4 times, respectively
major
yes (co-administration study)
Comment: Drugs known to induce CYP2C19 or CYP3A4 (such as rifampin) may lead to decreased omeprazole serum levels. In a cross-over study in 12 healthy male subjects, St John’s wort, an inducer of CYP3A4, decreased the systemic exposure of omeprazole in CYP2C19 poor metabolisers (Cmax and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolisers (Cmax and AUC decreased by 49.6% and 43.9%, respectively)
minor
minor
minor
no
yes
yes (co-administration study)
Comment: Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease esomeprazole concentrations
yes
yes (pharmacogenomic study)
Comment: Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease esomeprazole concentrations; The CYP2C19 isoenzyme exhibits polymorphism in the metabolism of esomeprazole, since some 3% of Caucasians and 15–20% of Asians lack CYP2C19 and are termed poor metabolizers. At steady state, the ratio of AUC in poor metabolizers to AUC in the rest of the population (normal metabolizers) is approximately 2
PubMed

PubMed

TitleDatePubMed
Pharmacokinetic study of esomeprazole in the elderly.
2001
Which patients with ulcer- or reflux-like dyspepsia will respond favorably to omeprazole?
2001 Apr
Antireflux surgery in children suffering from reflux-associated respiratory disease?
2001 Apr
Pantoprazole and cyclosporine or tacrolimus.
2001 Apr
Maximal acid reflux control for Barrett's oesophagus: feasible and effective.
2001 Apr
Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.
2001 Apr
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
2001 Apr
A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer.
2001 Apr
Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.
2001 Apr 1
From the Food and Drug Administration.
2001 Apr 4
Differentiation between reinfection and recrudescence of helicobacter pylori strains using PCR-based restriction fragment length polymorphism analysis.
2001 Feb
Protective effect of famotidine, omeprazole, and melatonin against acetylsalicylic acid-induced gastric damage in rats.
2001 Feb
Improved high performance liquid chromatographic analysis of omeprazole in human plasma.
2001 Feb
Gastroesophageal reflux disease and Barrett's esophagus.
2001 Feb
[Suppressive effect of lansoprazole on anti-Candida activity of murine macrophages].
2001 Feb
Re: Ammonia cannot explain the effect of H. pylori on omeprazole-induced acid suppression.
2001 Feb
Recurrent ulcer bleeding: is intravenous omeprazole the solution?
2001 Feb
A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers.
2001 Feb
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
2001 Feb
Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
2001 Feb
Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer.
2001 Feb
Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication.
2001 Feb
Aggressive acid control: minimizing progression of Barrett's esophagus.
2001 Feb
Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease.
2001 Feb
[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
2001 Feb
[Usefulness of new triple therapy containing PPI].
2001 Feb
[Selection of antibiotics and planning of eradication for H. pylori infection].
2001 Feb
[Recent guidelines for the management of Helicobacter pylori infection].
2001 Feb
Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.
2001 Feb
[Prevalence and treatment of Helicobacter pylori in gastro-duodenal ulcers. An experience in Liege].
2001 Jan
Upper gastrointestinal bleeding as a metastatic manifestation of breast cancer: a case report and review of the literature.
2001 Jan
Approach to the patient with unexplained chest pain.
2001 Jan
Gastroesophageal reflux disease: extraesophageal manifestations and therapy.
2001 Jan
Management of GERD: medical versus surgical.
2001 Jan
[Ulcer therapy with a new proton pump inhibitor. One week of treatment is enough].
2001 Jan 11
Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis.
2001 Jan 15
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
2001 Mar
Electrochemical studies and differential pulse polarographic analysis of lansoprazole in pharmaceuticals.
2001 Mar
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
2001 Mar
Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.
2001 Mar
Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.
2001 Mar
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
2001 Mar
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication.
2001 Mar
Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast and Lanzor) in healthy volunteers.
2001 Mar
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
2001 Mar 29
Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.
2001 Mar 6
[Heartburn. Only a harmless symptom?].
2001 Mar 8
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
2001 Mar 9
New OTC drugs and devices 2000: a selective review.
2001 Mar-Apr
Omeprazole therapy and salivary flow rate in duodenal ulcer patients.
2001 Mar-Apr
Patents

Sample Use Guides

Active Duodenal Ulcer: 20 mg Once daily for 4 weeks. Some patients may require an addition 4 weeks. Gastric Ulcer: oral dose is 40 mg once daily for 4-8 weeks. Gastroesophageal Reflux Disease: The recommended adult oral dose for the treatment of patients with symptomatic GERD and no esophageal lesions is 20 mg daily for up to 4 weeks. The recommended adult oral dose for the treatment of patients with erosive esophagitis and accompanying symptoms due to GERD is 20 mg daily for 4 to 8 weeks.
Route of Administration: Oral
Pretreatment of omeprazole (10-6 - 10-4M) dose-dependently inhibits neutrophil adherence and respiratory burst induced by H. pylori. These evidences imply that omeprazole may exhibit a beneficial effect on H. pylori-associated gastric mucosal damage caused by activated neutrophils.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:00:46 UTC 2021
Edited
by admin
on Fri Jun 25 21:00:46 UTC 2021
Record UNII
KG60484QX9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OMEPRAZOLE
EP   GREEN BOOK   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
OMEPRAZOLE [JAN]
Common Name English
OMEPRAZOLE COMPONENT OF ZEGERID
Common Name English
5-METHOXY-2-(((4-METHOXY-3,5,-DIMETHYL-2-PYRIDINYL)-METHYL)SULPHINYL)-1H-BENZIMIDAZOLE
Common Name English
NSC-759192
Code English
NSC-751450
Code English
1H-BENZIMIDAZOLE, 5-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-
Systematic Name English
OMEPRAZOLE COMPONENT OF YOSPRALA
Brand Name English
OMEPRAZOLE [USP]
Common Name English
OMEPRAZOLE [USP-RS]
Common Name English
OMEPRAZOLE [USP MONOGRAPH]
Common Name English
OMEPRAZOLE [HSDB]
Common Name English
OMEPRAZOLE [MART.]
Common Name English
LOSEC
Brand Name English
H-168/68
Code English
5-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDYL)METHYL)SULFINYL)BENZIMIDAZOLE
Systematic Name English
OMEPRAZOLE [MI]
Common Name English
OMEPRAZOLE [GREEN BOOK]
Common Name English
ZEGERID COMPONENT OMEPRAZOLE
Common Name English
OMEPRAZOLE [WHO-DD]
Common Name English
(RS)-6-METHOXY-2-((4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YL) METHYLSULFINYL)-1H-BENZO(D)IMIDAZOLE
Systematic Name English
OMEPRAZOLE [INN]
Common Name English
H 168/68
Code English
OMEPRAZOLE [VANDF]
Common Name English
OMEPRAZOLE [ORANGE BOOK]
Common Name English
OMEPRAZOLE [USAN]
Common Name English
YOSPRALA COMPONENT OMEPRAZOLE
Brand Name English
Classification Tree Code System Code
WHO-ATC A02BD05
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-VATC QA02BD01
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-ATC A02BC01
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-VATC QA02BD05
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
CFR 21 CFR 520.1615
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
LIVERTOX 710
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
NDF-RT N0000175525
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
FDA ORPHAN DRUG 446014
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-ATC A02BD01
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-VATC QA02BC01
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
NCI_THESAURUS C29723
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 17.1
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
NDF-RT N0000000147
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
Code System Code Type Description
MERCK INDEX
M8209
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY Merck Index
MESH
D009853
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
RXCUI
7646
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C716
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
NDF-RT
N0000182140
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
CAS
73590-58-6
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
WIKIPEDIA
OMEPRAZOLE
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
PUBCHEM
4594
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
USP_CATALOG
1478505
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY USP-RS
EPA CompTox
73590-58-6
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
DRUG BANK
DB00338
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
FDA UNII
KG60484QX9
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
HSDB
3575
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
EVMPD
SUB09439MIG
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
ChEMBL
CHEMBL1503
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
IUPHAR
4279
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
LACTMED
Omeprazole
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
DRUG CENTRAL
1990
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
INN
5081
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TARGET -> INHIBITOR
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INDUCER
ENANTIOMER -> RACEMATE
Related Record Type Details
METABOLITE INACTIVE -> PARENT
SUBSTRATE
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Impurities F and G: maximum 350 ppm for the sum of the contents
EP
IMPURITY -> PARENT
Impurities F and G: maximum 350 ppm for the sum of the contents
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Hepatic Imairment
PHARMACOKINETIC